DOCSLIB.ORG

Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0040020 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0040020 A1 US 20190040020A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 / 0040020 A1 Eriksson et al. (43 ) Pub . Date : Feb . 7 , 2012019 ( 54 ) TETRAZOLE DERIVATIVES AS A61K 45 / 06 (2006 .01 ) CYTOCHROME P450 INHIBITORS A61L 31/ 16 (2006 . 01) ( 52 ) U . S . CI. ( 71 ) Applicant : C26 Bioscience AB , Örebro (SE ) CPC .. .. CO7D 257/ 04 ( 2013 .01 ) ; A61L 31/ 16 ( 72 ) Inventors : Leif Eriksson , Göteborg (SE ); Allan ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; A61K 31/ 41 Sirsjö , Örebro (SE ) ; Åke Strid , Örebro (2013 . 01 ) (SE ) (57 ) ABSTRACT ( 21 ) Appl. No. : 16 /076 , 571 According to the invention there is provided a compound of formula I , wherein Rl and R2 have meanings given in the ( 22 ) PCT Filed : Feb . 10 , 2017 description , which compounds are useful in the treatment of ( 86 ) PCT No .: PCT/ GB2017 /050361 skin disorders and other diseases . $ 371 ( C ) ( 1 ), ( 2 ) Date : Aug . 8, 2018 (30 ) Foreign Application Priority Data Feb . 12 , 2016 (GB ) .. .. 1602572 .8 Publication Classification (51 ) Int. Ci. C07D 257704 ( 2006 .01 ) A61K 31 /41 ( 2006 .01 ) Patent Application Publication Feb . 7 , 2019 Sheet 1 of 5 US 2019 /0040020 A1 0.001 * 0.01 * 0.1 Material(UM)Test 1AFigure * 1 * 10 Control . 2 0 values relative CYP26B1 Patent Application Publication Feb . 7 , 2019 Sheet 2 of 5 US 2019 / 0040020 A1 * 0.001 * 0.01 .1 * 0 TestMaterial(UM) Figure1B * 1 * 10 Control values relative RARB Patent Application Publication Feb . 7 , 2019 Sheet 3 of 5 US 2019 /0040020 A1 * combination bothof new candidate Figure2B * atRA Control values relative RARB * ofboth * newcandidatecombination Figure2A * atRA Control attention a nd wewwwww values relative CYP26B1 Patent Application Publication Feb . 7 , 2019 Sheet 4 of 5 US 2019 / 0040020 A1 * empty vector * 10um Figure3B * lum CYP26B1 30000 25000 20000 15000 10000 5000 protein mg/ dpm RA] H [ * 10um * lum Figure3A Control 60000 50000 40000 30000 20000 10000 protein mg/ dpm RA] H [ Patent Application Publication Feb . 7 , 2019 Sheet 5 of 5 US 2019 / 0040020 A1 Newcandidate5uM+50nMatRA *Newcandidate25uM+50nMatRA control resepigeratRA50nM - 10min 5min Figure4 min1 me www. 30sec tortutofoto r httsuttuto 10sec secO 25000 20000 15000 10000 5000 DPM atRA ] BH[ US 2019 /0040020 A1 Feb . 7 , 2019 TETRAZOLE DERIVATIVES AS has been suggested that the therapeutic effects of atRA are CYTOCHROME P450 INHIBITORS undermined by its rapid in vivo metabolism and catabolism by cytochrome P450 enzymes (CYPs ) . FIELD OF THE INVENTION [ 0009 ] Emerging evidence , both clinical and molecular, [ 0001 ] The present invention relates to new compounds indicates that retinoids may also be used to treat atheroscle and their use in medicine . More specifically , it relates to the rotic lesions and restenosis phenomena in cardiovascular use of compounds in the treatment of diseases and condi disease . Although the data from clinical trials examining the tions in which a retained cellular level of endogenous effect of vitamin A and vitamin A precursors on cardiac all - trans retinoic acid (atRA ) is beneficial through the inhi events have been contradictory , these data do suggest that bition of the enzyme CYP26B1 responsible for degradation retinoids do influence fundamental processes relevant to of atRA . atherosclerosis . Preclinical cellular and animal model stud ies support these concepts . Retinoids exhibit complex effects BACKGROUND OF THE INVENTION on proliferation , growth , differentiation and migration of [0002 ] Retinoic acid (RA ) is a critical signaling molecule vascular smooth muscle cells (VSMC ), including responses in both embryonic development and in post -natal life . RA is to injury and atherosclerosis . Retinoids also appear to exert the active metabolite of Vitamin A (retinol ) and exists in important inhibitory effects on thrombosis and inflammatory several isoforms, of which all - trans RA ( atRA ) , 13 - cisRA responses relevant to atherogenesis . Recent studies suggest and 9 , 13 - dicisRA are those most commonly detected in the that retinoids may also be involved in vascular calcification human body . Endogenous RA isomers are essential for stem and endothelial function , for example , by modulating nitric cell and neuronal differentiation , in regulating insulin stimu oxide pathways. lated glucose secretion , in regulating cell cycles and apop tosis , and in the maintenance of healthy skin , epithelia and 0010 ] Treatment by addition of exogenous atRA or one of the immune system . A high level of cellular atRA has its isoforms is therefore often the main treatment or a efficient antiproliferatory effects . co - treatment for these conditions . 10003 ] The biological activity of the RAs is mainly mani 10011 ] Although atRA - treatment as such is a successful fested by their binding to nuclear RA receptors (RARS ) , treatmentmodality , excessive intake of Vitamin A leads to a which leads to increased transcription of the target genes . syndrome known as hypervitaminosis A or retinoic acid The observed effects on gene transcription are thus depen syndrome, characterized by erythema , weight and hair loss , dent on cellular concentrations of atRA and on the expres bone pain , liver problems, build - up of fluid in lungs and in sion levels of the three RAR isoforms. Catabolism of the rest of the body , kidney failure , skin and eye irritations , cellular atRA is achieved by members of the cytochrome and teratogenicity . In addition , patients may also develop P450 family 26 (CYP26 ) , and in particular CYP26A1 in the RA resistance during treatment. liver and CYP26B1 in other adult human tissues. Inhibition [0012 ] To overcome these severe and unwanted side of members of the CYP26 family may therefore provide a effects, the use of selective CYP26 inhibitors has been means to ensure elevated levels of endogenous atRA in the proposed , possibly together with mild addition of exogenous cells . Such inhibitors are referred to as retinoic acid metabo atRA . The most common and well - studied of these RAM lism blocking agents , RAMBAS . BAs are ketoconazole , liarozole and talarozole . Albeit suc 10004 ] A number of indications have been shown to lead cessful to varying degrees in cell tests , animal models , and to local up -regulation of atRA degrading enzymes and to clinical trials , their efficacy is not extraordinary. The main respond favorably to treatment using exogenous atRA ( or focus for all three RAMBAs has in this context been to target one of its isoforms) due to its ability to down - regulate cell CYP26A1 for treatment of psoriasis , the rare disease kera proliferation . tinocytic ichthyosis , and prostate cancer . [ 0005 ] These indications include dermatological condi tions such as severe acne /rosacea , psoriasis , and keratino [0013 ] The listing or discussion of an apparently prior cytic ichthyosis . Synthetic vitamin A derivatives ( retinoids ) published document in this specification should not neces have long been the mainstay of treatment for several disor sarily be taken as an acknowledgement that the document is ders of keratinization , notably the ichthyoses and severe part of the state of the art or is common general knowledge . acne . Some forms of psoriasis also respond well . [0014 ] The inventors have surprisingly found that the [ 0006 ]. In terms of cosmetic anti -aging applications , pre compounds disclosed herein may be useful as inhibitors of scribed creams containing atRA ( intended for treatment of CYP26 , in particular the CYP26B1 isoform . acne ) , are the only preparations with proven effect against fine lines and wrinkles . [ 0007 ] Recent studies have shown that retinoic acid pro SUMMARY OF THE INVENTION tects against intestinal inflammation mainly by shifting the Treg / Th17 profile , allowing for the treatment of inflamma [ 0015 ] According to the present invention , there is pro tory bowel diseases . vided a compound of formula I : [0008 ] atRA has been successful in the chemotherapy treatment of various cancer forms such as neuroblastoma (NBI ) , acute promyelocytic leukaemia (APL ), prostate can cer and to some extent post -menopausal breast cancer . One of the most impressive effects of atRA has been observed in the treatment of APL . Treatment of patients suffering from APL with high dose of atRA resulted in complete remission . Furthermore , several experiments in animals have demon strated that atRA inhibited the induction and caused the N disappearance of prostate tumors. In spite of these encour N aging results , knowledge of the effects of prolonged atRA therapy on human cancers in the clinic has been scarce . It US 2019 /0040020 A1 Feb . 7 , 2019 wherein : the proviso above will become redundant ( for example , R represents hydrogen or C1- 2 alkyl , which alkyl group is where it is stated that R is a C1- 2 alkyl group substituted by optionally substituted by one or more fluorine atoms; and one or more fluorine atoms, or R is a group other than R ? represents hydrogen or a carboxylic acid protecting hydrogen ) . group ; 10023 ] In an embodiment of the invention , there is pro or a pharmaceutically acceptable salt thereof , vided a compound of formula I wherein R is a methyl provided that the compound or pharmaceutically acceptable group , optionally substituted by one or more fluorine atoms . salt thereof is not the compound of formula II : For example , in a further embodiment, R represents methyl or trifluoromethyl. [ 0024 ] In an alternative embodiment, R ' represents hydro gen , methyl or ethyl.
Load more

Recommended publications
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • © Copyright 2018 Faith M. Stevison
    © Copyright 2018 Faith M. Stevison In Vitro to In Vivo Translation of Complex Drug-Drug Interactions Involving Retinoic Acid Faith M. Stevison A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2018 Reading Committee: Nina Isoherranen, Chair Kenneth E. Thummel Yvonne S. Lin Program Authorized to Offer Degree: Pharmaceutics University of Washington Abstract In Vitro to In Vivo Translation of Complex Drug-Drug Interactions Involving Retinoic Acid Faith M. Stevison Chair of the Supervisory Committee: Professor and Vice Chair, Nina Isoherranen Pharmaceutics all-trans-retinoic acid (atRA), the active metabolite of vitamin A, is a ligand for several nuclear receptors and acts as a critical regulator of many physiological processes. The cytochrome P450 26 (CYP26) enzymes are responsible for atRA clearance and are potential drug targets to increase concentrations of endogenous atRA in a tissue-specific manner. The first project of this thesis aimed to establish the relationship between CYP26 inhibition, by the potent CYP26A1 and B1 inhibitor talarozole, and altered atRA concentrations in tissues, and to quantify the increase in endogenous atRA concentrations necessary to alter atRA signaling in target organs. The second part of this thesis focused on evaluating exogenous atRA and retinoid dosing on gene regulation. Several in vitro and preclinical studies have suggested that atRA down-regulates CYP2D6 expression and activity. Both atRA and its stereoisomer 13-cis retinoic acid (13cisRA) are used clinically, and steady state exposures of atRA are similar after dosing with atRA or 13cisRA. The second aim of this thesis was to determine whether 13-cis retinoic acid (13cisRA) or its active metabolites, atRA and 4-oxo-13cisRA, cause a drug-drug interaction (DDI) with CYP2D6, decreasing the clearance of the CYP2D6 probe dextromethorphan.
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APC Min/+ Mice
    Published OnlineFirst September 16, 2016; DOI: 10.1158/2326-6066.CIR-15-0038 Research Article Cancer Immunology Research Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/þ Mice Hweixian Leong Penny1, Tyler R. Prestwood1, Nupur Bhattacharya1, Fionna Sun1, Justin A. Kenkel1, Matthew G. Davidson1, Lei Shen1, Luis A. Zuniga2, E. Scott Seeley1, Reetesh Pai3, Okmi Choi1, Lorna Tolentino1, Jinshan Wang4, Joseph L. Napoli4, and Edgar G. Engleman1 Abstract Chronic intestinal inflammation accompanies familial adeno- exhibited further reductions in intestinal RA with concomitant matous polyposis (FAP) and is a major risk factor for colorectal increases in inflammation and tumor burden. Conversely, resto- cancer in patients with this disease, but the cause of such inflam- ration of RA by pharmacologic blockade of the RA-catabolizing mation is unknown. Because retinoic acid (RA) plays a critical role enzyme CYP26A1 attenuated inflammation and diminished in maintaining immune homeostasis in the intestine, we hypoth- tumor burden. To investigate the effect of RA deficiency on the esized that altered RA metabolism contributes to inflammation gut immune system, we studied lamina propria dendritic cells and tumorigenesis in FAP. To assess this hypothesis, we analyzed (LPDC) because these cells play a central role in promoting þ RA metabolism in the intestines of patients with FAP as well as tolerance. APCMin/ LPDCs preferentially induced Th17 cells, but þ APCMin/ mice, a model that recapitulates FAP in most respects. reverted to inducing Tregs following restoration of intestinal RA We also investigated the impact of intestinal RA repletion and in vivo or direct treatment of LPDCs with RA in vitro.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Talarozole R enantiomer Catalog Number : T13422L CAS Number : 870093-23-5 Molecular Formula : C21H23N5S Molecular Weight : 377.51 Description: Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 51 mg/mL (135.10 mM) Solubility ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) Others In vitro Activity Talarozole R enantiomer treatment increased the mRNA expression of CRABP2, KRT4, CYP26A1, and CYP26B1 dose- dependently, and decreased the expression of KRT2 and IL-1alpha compared with vehicle-treated skin. No mRNA change in retinol-metabolizing enzymes was obtained. There was no induction of epidermal thickness or overt skin inflammation in talarozole-treated skin. Immunofluorescence analysis confirmed the upregulation of KRT4 protein, but no upregulation of CYP26A1 and CYP26B1 expression was detected [1] [2]. In vivo Activity Talarozole R enantiomer slightly diffused into the skin only when dissolved in propylene glycol, isopropyl myristate, or ethanol. Although only 0.1% of the dose applied was found in the skin itself after 12-24 h, this was sufficient to achieve local concentrations well above the half-maximal inhibitory concentration value for talarozole. The distribution of talarozole within the skin was investigated: 80% was located in the epidermis, while the remaining 20% was found in the dermis [3]. Reference 1. Pavez Loriè E, Cools M, Borgers M, Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis.
    [Show full text]
  • Atra) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous Atra Signaling
    1521-009X/45/7/846–854$25.00 https://doi.org/10.1124/dmd.117.075341 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:846–854, July 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling Faith Stevison, Cathryn Hogarth, Sasmita Tripathy, Travis Kent, and Nina Isoherranen Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (F.S., S.T., N.I.); and School of Molecular Biosciences and the Center for Reproductive Biology, Washington State University, Pullman, Washington (C.H., T.K.) Received February 1, 2017; accepted April 18, 2017 ABSTRACT All-trans retinoic acid (atRA), the active metabolite of vitamin A, is a atRA concentrations in tissues. Following a single 2.5-mg/kg dose of Downloaded from ligand for several nuclear receptors and acts as a critical regulator of talarozole to mice, atRA concentrations increased up to 5.7-, 2.7-, and many physiologic processes. The cytochrome P450 family 26 (CYP26) 2.5-fold in serum, liver, and testis, respectively, resulting in induction enzymes are responsible for atRA clearance, and are potential drug of Cyp26a1 in the liver and testis and Rar b and Pgc 1b in liver. The targets to increase concentrations of endogenous atRA in a tissue- increase in atRA concentrations was well predicted from talarozole specific manner. Talarozole is a potent inhibitor of CYP26A1 and pharmacokinetics and in vitro data of CYP26 inhibition. After multiple CYP26B1, and has shown some success in clinical trials.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Cytochrome P450 Cyps
    Cytochrome P450 CYPs Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism. www.MedChemExpress.com 1 Cytochrome P450 Inhibitors, Activators & Modulators (+)-Ketoconazole (3S,5S)-Atorvastatin ((+)-Ketoconazol; (+)-R 41400) Cat. No.: HY-B0105A Cat. No.: HY-B0589C (+)-Ketoconazole ((+)-R 41400) is an imidazole (3S,5S)-Atorvastatin is a inactive enantiomer of anti-fungal agent, a CYP3A4 inhibitor. Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Purity: 99.51% Purity: ≥95.0% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg (Rac)-Brassinazole 1-Aminobenzotriazole Cat.
    [Show full text]
  • Cytochrome P450 Cyps
    Cytochrome P450 CYPs Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism. www.MedChemExpress.com 1 Cytochrome P450 Inhibitors & Modulators (+)-Ketoconazole (-)-Cephaeline dihydrochloride Cat. No.: HY-B0105A (NSC 32944) Cat. No.: HY-N2260 Bioactivity: (+)-Ketoconazole is an imidazole anti-fungal agent, a CYP3A4 Bioactivity: (-)-Cephaeline dihydrochloride is an enantiomer of Cephaeline inhibitor. Target: CYP3A4 (+)-Ketoconazole, an imidazole dihydrochloride. Cephaeline dihydrochloride is a selective anti-fungal agent, has often produced features of androgen CYP2D6 inhibtor with IC50 of 121 μM. deficiency including decreased libido, gynecomastia, impotence, oligospermia, and decreased testosterone levels, in… Purity: 99.51% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 2 mg, 5 mg 10 mg, 50 mg 1-Aminobenzotriazole 1-Ethynylnaphthalene (ABT; 3-Aminobenzotriazole) Cat.
    [Show full text]
  • Alterations in Endogenous Retinoids with Acute UVB Exposure and in the Progression of Cutaneous Squamous Cell Carcinoma
    Alterations in Endogenous Retinoids with Acute UVB Exposure and in the Progression of Cutaneous Squamous Cell Carcinoma THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Katherine Gressel Graduate Program in Human Nutrition The Ohio State University 2015 Master's Examination Committee: Dr. Helen Everts, Advisor Dr. Earl Harrison Dr. Tatiana Oberyszyn Copyrighted by Katherine Gressel 2015 Abstract Exposure to UVB light is the largest risk factor for the development of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the United States. UVB exposure causes many changes to occur in the skin such as epidermal thickening, hyperproliferation, and alterations to epidermal differentiation. Retinoids regulate the differentiation and proliferation of the epidermis. The purpose of this study is to examine how the expression of retinoid metabolism proteins in the epidermis is altered with acute UVB exposure and in the progression of cSCC. There is limited knowledge of how UVB exposure may affect this pathway; our results will allow us to gain a more complete understanding of changes in the entire retinoid metabolism pathway. We examined the expression of key retinoic acid metabolism proteins in the epidermis and hair follicle remnants 48 hours after UVB exposure in SKH-1 mice using immunohistochemistry. UVB exposure increased the expression of retinoid synthesis, degradation, and binding proteins. These changes in expression suggest that acute UVB exposure increases the synthesis of retinoic acid in the epidermis. Many of these proteins changed their localization in the epidermis, concentrating in the more differentiated cells of the stratum granulosum and stratum corneum.
    [Show full text]
  • Improved Homology Model of the Human All-Trans Retinoic Acid Metabolizing Enzyme CYP26A1
    molecules Article Improved Homology Model of the Human all-trans Retinoic Acid Metabolizing Enzyme CYP26A1 Mohamed K. A. Awadalla 1, Thamir M. Alshammari 2, Leif A. Eriksson 3,* and Patricia Saenz-Méndez 4 1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, P. O. Box 2440, 81451 Hail, Saudi Arabia; [email protected] 2 Department of Clinical Pharmacology, College of Pharmacy, University of Hail, P. O. Box 2440, 81451 Hail, Saudi Arabia; [email protected] 3 Department of Chemistry and Molecular Biology, University of Gothenburg, 40530 Gothenburg, Sweden 4 Computational Chemistry and Biology Group, Facultad de Química, UdelaR, 11800 Montevideo, Uruguay; [email protected] * Correspondence: [email protected]; Tel.: +46-031-786-9117 Academic Editor: Derek J. McPhee Received: 17 February 2016 ; Accepted: 9 March 2016 ; Published: 15 March 2016 Abstract: A new CYP26A1 homology model was built based on the crystal structure of cyanobacterial CYP120A1. The model quality was examined for stereochemical accuracy, folding reliability, and absolute quality using a variety of different bioinformatics tools. Furthermore, the docking capabilities of the model were assessed by docking of the natural substrate all-trans-retinoic acid (atRA), and a group of known azole- and tetralone-based CYP26A1 inhibitors. The preferred binding pose of atRA suggests the (4S)-OH-atRA metabolite production, in agreement with recently available experimental data. The distances between the ligands and the heme group iron of the enzyme are in agreement with corresponding distances obtained for substrates and azole inhibitors for other cytochrome systems. The calculated theoretical binding energies agree with recently reported experimental data and show that the model is capable of discriminating between natural substrate, strong inhibitors (R116010 and R115866), and weak inhibitors (liarozole, fluconazole, tetralone derivatives).
    [Show full text]
  • ( 12 ) United States Patent
    US009963439B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,963 , 439 B2 Diaz et al. ( 45 ) Date of Patent: May 8 , 2018 ( 54 ) SPECIFIC INHIBITORS OF CYTOCHROME FOREIGN PATENT DOCUMENTS P450 26 RETINOIC ACID HYDROXYLASE CN 102503857 6 / 2012 (71 ) Applicants : University of Washington Through its EP 0722928 A1 7 /1996 Center for Commercialization , Seattle, (Continued ) WA (US ) ; UNIVERSITY OF MONTANA , Missoula , MT (US ) OTHER PUBLICATIONS (72 ) Inventors : Philippe Diaz , Missoula , MT (US ); Ohta (Biorganic and Medicinal Chemistry Letters ; 23 , 2013 , 81 -84 ; Nina Isoherranen , Seattle , WA (US ) ; available online Nov. 15 , 2012 ). * Brian Buttrick , Seattle , WA (US ) ; (Continued ) Nicolas Guilloteau , Missoula , MT ( US ) Primary Examiner — Pancham Bakshi ( 73 ) Assignees: University of Washington Through Its (74 ) Attorney , Agent, or Firm — McDonnell Boehnen Center For Commercialization , Hulbert & Berghoff LLP Seattle , WA (US ) ; University of ( 57 ) ABSTRACT Montana , Missoula , MT (US ) The present disclosure is generally directed to compositions ( * ) Notice : Subject to any disclaimer, the term of this and methods for treating diseases that are ameliorated by the inhibition ofCYP26 mediated retinoic acid metabolism . The patent is extended or adjusted under 35 compositions comprise compounds of formula ( I ) . A rep U . S . C . 154 ( b ) by 0 days . days . reid50000060307390 IB /345 nullsents aryl optionally sub stituted with one , two, three , or four groups that are each ( 21) Appl . No. : 14 /912 , 479 independently halogen , cyano , nitro , C1- 6 alkyl , C1- 6 haloalkyl, - NH2, — NH ( C . - C . alkyl) , - N ( C / - C alkyl) 2 , (22 ) PCT Filed : Aug. 20 , 2014 OH , C , - Cô alkoxy , and C . - C6 haloalkoxy ; X is a bond , CH , CHR — - C = CHR NR4 — , ( 86 ) PCT No.
    [Show full text]